| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
101,390,000 |
| Market
Cap: |
1.64(B) |
| Last
Volume: |
668,805 |
Avg
Vol: |
666,996 |
| 52
Week Range: |
$12.32 - $16.78 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Innoviva is a company with a portfolio of royalties and other healthcare assets. Co.'s royalty portfolio contains respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA® and TRELEGY® ELLIPTA®. Co. is entitled to royalty payments made by GSK under its agreements that assigned to Theravance Respiratory Company, LLC (TRC), including TRELEGY® ELLIPTA® and any other product or combination of products that may be discovered or developed in the future under the Long-Acting Beta2 Agonist Collaboration Agreement and the Strategic Alliance Agreement with GSK, which have been assigned to TRC other than RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
664,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$8,468,005 |
| Total People Bought |
0 |
0 |
0 |
2 |
| Total Buy Transactions |
0 |
0 |
0 |
12 |
| Total Shares Sold |
0 |
0 |
10,994 |
10,994 |
| Total Sell Value |
$0 |
$0 |
$153,810 |
$153,810 |
| Total People Sold |
0 |
0 |
1 |
1 |
| Total Sell Transactions |
0 |
0 |
1 |
1 |
| End Date |
2024-03-21 |
2023-12-19 |
2023-06-20 |
2022-06-20 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Blum Leonard M |
Sr VP, Chief Comm. Officer |
• – – |
2011-02-11 |
4 |
A |
$0.00 |
$0 |
D/D |
112,500 |
281,932 |
|
- |
|
| Mammen Mathai |
SVP, Research & Early Clin Dev |
• – – |
2011-01-28 |
4 |
OE |
$8.53 |
$83,869 |
D/D |
9,838 |
143,823 |
|
- |
|
| Gunderson Robert V Jr |
Director |
– • – |
2010-12-22 |
4 |
A |
$0.00 |
$0 |
D/D |
768 |
66,164 |
|
- |
|
| Whitesides George M |
Director |
– • – |
2010-12-22 |
4 |
A |
$0.00 |
$0 |
D/D |
1,152 |
556,571 |
|
- |
|
| Levine Arnold J |
Director |
– • – |
2010-12-22 |
4 |
A |
$0.00 |
$0 |
D/D |
768 |
47,960 |
|
- |
|
| Drazan Jeffrey M |
Director |
– • – |
2010-12-22 |
4 |
A |
$0.00 |
$0 |
D/D |
63,729 |
109,595 |
|
- |
|
| Drazan Jeffrey M |
Director |
– • – |
2010-12-22 |
4 |
D |
$0.00 |
$0 |
I/I |
(2,747,794) |
0 |
|
- |
|
| Young William D |
Director |
– • – |
2010-12-10 |
4 |
S |
$26.64 |
$143,243 |
D/D |
(5,377) |
23,377 |
|
- |
|
| Young William D |
Director |
– • – |
2010-12-10 |
4 |
OE |
$8.53 |
$91,678 |
D/D |
10,754 |
28,754 |
|
- |
|
| Aguiar Michael W |
Sr VP, Chief Financial Officer |
• – – |
2010-12-03 |
4 |
S |
$26.51 |
$265,100 |
D/D |
(10,000) |
109,601 |
|
- |
|
| Brinkley David L |
Head of Business Dev. |
• – – |
2010-12-01 |
4 |
S |
$25.07 |
$501,400 |
D/D |
(20,000) |
38,359 |
|
- |
|
| Brinkley David L |
Head of Business Dev. |
• – – |
2010-12-01 |
4 |
OE |
$3.10 |
$47,353 |
D/D |
15,275 |
58,359 |
|
- |
|
| Glaxosmithkline Plc |
10% Owner |
– – • |
2010-11-29 |
4 |
B |
$22.50 |
$129,375,000 |
I/I |
5,750,000 |
5,750,000 |
1.5 |
- |
|
| Shafer Bradford J |
Sr VP, Gen. Counsel, Secretary |
• – – |
2010-11-20 |
4 |
D |
$22.52 |
$54,116 |
D/D |
(2,403) |
257,674 |
|
- |
|
| Brinkley David L |
Head of Business Dev. |
• – – |
2010-11-20 |
4 |
D |
$22.52 |
$39,793 |
D/D |
(1,767) |
43,084 |
|
- |
|
| Winningham Rick E |
Chief Executive Officer |
• • – |
2010-11-20 |
4 |
D |
$22.52 |
$125,099 |
D/D |
(5,555) |
181,323 |
|
- |
|
| Mammen Mathai |
SVP, Research & Early Clin Dev |
• – – |
2010-11-20 |
4 |
D |
$22.52 |
$57,021 |
D/D |
(2,532) |
133,985 |
|
- |
|
| Aguiar Michael W |
Sr VP, Chief Financial Officer |
• – – |
2010-11-20 |
4 |
D |
$22.52 |
$63,371 |
D/D |
(2,814) |
119,601 |
|
- |
|
| Mammen Mathai |
SVP, Research & Early Clin Dev |
• – – |
2010-10-26 |
4 |
A |
$0.00 |
$0 |
D/D |
12,500 |
136,517 |
|
- |
|
| Shafer Bradford J |
Sr VP, Gen. Counsel, Secretary |
• – – |
2010-10-26 |
4 |
A |
$0.00 |
$0 |
D/D |
12,500 |
260,077 |
|
- |
|
| Blum Leonard M |
Sr VP, Chief Comm. Officer |
• – – |
2010-10-26 |
4 |
A |
$0.00 |
$0 |
D/D |
12,500 |
169,432 |
|
- |
|
| Brinkley David L |
Head of Business Dev. |
• – – |
2010-10-26 |
4 |
A |
$0.00 |
$0 |
D/D |
12,500 |
44,851 |
|
- |
|
| Aguiar Michael W |
Sr VP, Chief Financial Officer |
• – – |
2010-10-26 |
4 |
A |
$0.00 |
$0 |
D/D |
12,500 |
122,415 |
|
- |
|
| Winningham Rick E |
Chief Executive Officer |
• • – |
2010-10-26 |
4 |
A |
$0.00 |
$0 |
D/D |
27,500 |
186,878 |
|
- |
|
| Fore Henrietta |
Director |
– • – |
2010-10-20 |
4 |
A |
$0.00 |
$0 |
D/D |
9,000 |
9,000 |
|
- |
|
704 Records found
|
|
Page 21 of 29 |
|
|
0.06 (0.37%) 
